Navigation Links
Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
Date:7/22/2014

OXFORD, England, July 22, 2014 /PRNewswire/ --


Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®).  Based on these results, the company intends to transfer the formulation production process to a contract manufacturing organisation (CMO), and to advance Glide octreotide delivered with the needle-free Glide solid dose injector (SDI®) into clinical trials in 2015.

The pre-clinical study compared the pharmacokinetic profile of the most widely used clinical dose of Sandostatin (100 mcg) with that of Glide's octreotide solid dose formulation.  The results demonstrated that there was no statistical difference between the two profiles (p<0.05).  Octreotide products are currently approved for use in the treatment of acromegaly and certain neuroendocrine tumours with the market for immediate release liquid formulations estimated to be in excess of $150 million.

Dr Mark Carnegie-Brown, Glide Pharma's CEO, commented, "These results represent a significant milestone, both in the development of our final clinical formulation for Glide octreotide and of our scale-up capabilities.  Together, these enable us to transfer the formulation manufacturing process to a CMO later in the year.  This progress is mirrored in our device scale-up programme, and as a result we plan to complete an octreotide clinical proof-of-concept study with our Glide SDI® device in 2015."

About Glide Pharma 

Glide Pharma is a pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines.  The company's products are based on its p
'/>"/>

SOURCE Glide Pharma
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter
2. Verathon, maker of GlideScope video laryngoscopes, provides free educational DVD to promote best practices in pediatric airway management.
3. Glide Pharma Completes £14.0 Million ($21.4 Million) Fundraising for Scale Up of Drug and Device Manufacturing Processes and Product Development
4. TriReme Medical and Japanese Partner Century Medical, Inc., Receive Shonin Approval for GliderXtreme PTA Catheter in Japan
5. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
6. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
7. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
8. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
9. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
10. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The role of the Medical Science Liaison ... hasn,t changed: face-to-face meetings are seen as the best ... Leaders. Yet at the same time face-to-face ... interaction, field medical teams within the pharmaceutical sector are ... just one of the challenges addressed in " Medical ...
(Date:2/27/2015)... , Feb. 27, 2015  Acsis Inc., the ... serialization solutions, announced today that John DiPalo , ... Supply & Demand Chain Executive 2015 Provider ... who are leading initiatives to help prepare their companies, ... today,s business climate. This year,s list of Provider Pros ...
(Date:2/27/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced ... loss (NOL) guidance and its cash guidance ending the ... financial results were due in large part to the ... from its partners.  Isis, pro forma NOL of $16.3 ... its 2013 NOL of $40.2 million. On a GAAP ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
... chemotherapy-soaked beads to choke off and kill cancerous ... research being presented at the 21st annual International ... a minimally invasive therapy that takes a two-pronged ... minimally invasive methods to deliver the beads (also ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced ... solution) has been accepted for review by the U.S. Food ... for Bepreve as an eye drop treatment for ocular itching ... review of ten months and has been given a user ...
Cached Medicine Technology:Chemoembolization Improving as Liver Cancer Treatment 2Chemoembolization Improving as Liver Cancer Treatment 3Chemoembolization Improving as Liver Cancer Treatment 4ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration 2ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration 3
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
(Date:2/28/2015)... With their commitment to achieving physical results and ... to their already robust library of oblique exercises. “Rope ... as, is often performed on a stationary piece of ... relatively safe manner and can be performed by individuals ... of “Rope Pulls” is located in the oblique exercises ...
(Date:2/28/2015)... 2015 The Classic Denture Center ... new special. Throughout all of March patients can ... This service can help overall mouth health ... Patients may notice certain symptoms that suggest the denture ... symptoms include: , 1.    Pain, clicking, and popping in the ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate ... provide business consulting services in addition to a variety ... and succession planning. Company finances are a complicated matter ... top of this, complex Canadian tax laws can make ... a result, Mew and Company works to advise their ...
(Date:2/28/2015)... February 28, 2015 Indosoft Inc ... suite for Asterisk, are pleased to announce the development ... 5.7 and 5.8 versions of Q-Suite, this new version ... a number of new features to the leading edge ... , Q-Suite 5.9 will add features to enhance security ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... The American Thoracic Society has released new official ... idiopathic pulmonary fibrosis (IPF). The statement replaces ATS ... in the epidemiology, etiology, diagnosis and management of ... pharmacologic and non-pharmacologic therapies and palliative care. , ...
... HealthDay Reporter , THURSDAY, March 17 (HealthDay News) ... scanners that emit radiation are tiny, experts say, but disagreement ... mass of travelers who pass through them every year. ... of Radiology , radiation experts David J. Brenner and ...
... cartilage implants created using stem cells can only be ... measure before the almost inevitable need for total joint ... are investigating the possibilities of a biologically-engineered synthetic liquid ... by offering a one stop, permanent solution. ...
... to hospital patients, coordinating and providing direct care and delivering it ... that each of its patient-care units has an adequate number of ... of hours nurses work known as the "target level" ... of patients and their need for care. Too many nurses can ...
... HealthDay Reporter , WEDNESDAY, March 16 (HealthDay News) ... a large hospital, more patients died, a new study discovered. ... nursing shortages and cost-cutting, in that the focus should shift ... research, appearing in the March 17 issue of the ...
... HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... the nuclear complex in Japan did manage to reach ... the unfolding disaster across the Pacific Ocean will make ... of any radioactive plume reaching the United States are ...
Cached Medicine News:Health News:ATS issues joint statement on the treatment of idiopathic pulmonary fibrosis 2Health News:ATS issues joint statement on the treatment of idiopathic pulmonary fibrosis 3Health News:ATS issues joint statement on the treatment of idiopathic pulmonary fibrosis 4Health News:Not Even Experts Agree on Safety of Airport Scanners 2Health News:Not Even Experts Agree on Safety of Airport Scanners 3Health News:Liquid biomaterials take stem cell therapy to new level 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 3Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 3Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 4
... Integra 400 plus, innovation means 4 ... reaction cuvettes and im-proved operator ergonomics. ... and ease-of-use required for true workload ... possible with only one analytical platform, ...
... Advia 2400 has minimal ... (as low as 2 ... (40 L/hour) thus maximizing ... universal rack handler facilitates ...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
Intended for the quantitative determination of iron in serum. Reaction: Endpoint. Wavelength: 595 nm. Linearity: 500 g/dL (89.5 mol/L). Two vials, liquid reagents....
Medicine Products: